30033-25-1

Basic information

• Product Name: L-Tyrosine, 3-hydroxy-N-[(phenylmethoxy)carbonyl]-
• Synonyms: N-(benzyloxycarbonyl)-3-(3,4-dihydroxyphenyl)-L-alanine;(S)-2-Benzyloxycarbonylamino-3-(3,4-dihydroxy-phenyl)-propionic acid
• CAS NO: 30033-25-1
• Molecular Formula: C17H17NO6
• Molecular Weight: 331.325
• Mol File: 30033-25-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 618.2±55.0 °C(Predicted)
• Density: 1.400±0.06 g/cm3(Predicted)
• CAS DataBase Reference: L-Tyrosine, 3-hydroxy-N-[(phenylmethoxy)carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Tyrosine, 3-hydroxy-N-[(phenylmethoxy)carbonyl]-(30033-25-1)
• EPA Substance Registry System: L-Tyrosine, 3-hydroxy-N-[(phenylmethoxy)carbonyl]-(30033-25-1)

Safety Data

• Hazardous Substances Data: 30033-25-1(Hazardous Substances Data)

Upstream product

• 59-92-7 levodopa 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 122769-76-0 L-N-benzyloxycarbonyl-3-(4-benzyloxy-3-hydroxyphenyl)alanine benzyl ester 
• 122769-75-9 (S)-benzyl 3-(3-(benzyloxy)-4-hydroxyphenyl)-2-(((benzyloxy)carbonyl)amino)propanoate 
• 1142016-27-0 N-(benzyloxycarbonyl)-3,4-dihydroxyphenylalanine tert-butyl ester 
• 1093125-20-2 N-(benzyloxycarbonyl)-3,4-dihydroxy-L-phenylalanine (9-methoxy-3-oxo-3H-benzo[f]benzopyran-1-yl)methyl ester 
• 213757-61-0 (S)-2-Benzyloxycarbonylamino-3-(3,4-bis-tert-butoxycarbonylmethoxy-phenyl)-propionic acid benzyl ester 
• 213757-62-1 (S)-2-Amino-3-(3,4-bis-tert-butoxycarbonylmethoxy-phenyl)-propionic acid 
• 37169-42-9 (S)-benzyl 2-(((benzyloxy)carbonyl)amino)-3-(3,4-dihydroxyphenyl)propanoate 

Relevant articles and documents

Carbidopa and L-Dopa Prodrugs and Methods of Use

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising admini

ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.